SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and social media users fiercely debate the administration's military strategy in the Strait of Hormuz, with community discussion highlighting friction over requests for allied support following recent escalations. The conversation is heavily polarized, featuring widespread speculation on potential economic fallout and criticism regarding the lack of a clear long-term geopolitical plan.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending following a GTC keynote where CEO Jensen Huang projected over $1 trillion in AI infrastructure demand through 2027, signaling massive long-term growth for the company's Blackwell and Vera Rubin platforms. While the announcement fueled initial volatility and intense debate among investors over the stock's valuation and the reality of meeting such high revenue targets, the community remains divided between those viewing the pullback as a buying opportunity and others skeptical of the company's ability to sustain its premium market position.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant traction as a critical infrastructure provider in the DeFi sector, driven by its recent integration of institutional-grade financial data and its unique position in supplying macroeconomic indicators to blockchain ecosystems. Community members are actively highlighting the project's institutional backing, revenue-sharing model through token buybacks, and its role as a core player in the emerging Real World Asset (RWA) narrative.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is trending as community members weigh the impact of the ASI merger and partnership integrations against a prolonged period of price volatility and FUD. While some investors are aggressively accumulating during the downturn, citing the project's long-term utility in the agentic AI sector, others remain skeptical, focusing on recent token supply dynamics and the broader underperformance of altcoins.

Electro Optic Systems Holdings Ltd. develops and produces products incorporating advanced electro-optic technologies for the aerospace market. It operates through the Space Systems and Defence Systems segments. The Space Systems segment is involved in ground products available to support the Australian and international space markets. The Defence Systems segment develops, manufactures, and markets advanced fire control, surveillance, and weapon systems to approved military customers. The company was founded by Benny Allan Greene in 1983 and is headquartered in Symonston, Australia.

Electro Optic Systems Holdings Ltd

Electro Optic Systems is gaining significant community attention as it secures multiple defense contracts for its counter-drone and laser weapon technologies, with investors highlighting the company's expanding backlog and strong performance in comparative military trials. The ongoing global demand for advanced, cost-effective air defense systems is driving discussions around the firm's strategic growth, international partnerships, and potential for increased market presence.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

Ripple (XRP) is experiencing high volatility as investors debate the legitimacy of recent price movements, with sentiment split between optimism over potential institutional adoption and skepticism regarding recurring sell-offs. The community remains deeply divided, with many actively trading around short-term price fluctuations while others hold long-term positions, waiting for clarity on regulatory milestones and market decoupling from Bitcoin.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community reacts to NOAA determining that the company's consolidated deep-sea mining application for the Clarion-Clipperton Zone is in substantial compliance, a regulatory milestone that paves the way for further review. Investors are actively discussing the implications of this expansion and the company's positioning alongside upcoming corporate developments, with many highlighting the stock as a critical play for domestic mineral security.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing intense market attention and a surge in trading volume driven by unconfirmed takeover rumors involving a large U.S.-based biopharmaceutical company. Investors are actively debating the potential for an M&A exit, comparing current valuations to historical biotech acquisition multiples while weighing the credibility of these reports against the company's established commercial growth.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is seeing a surge in sentiment driven by its growing enterprise utility, specifically high-profile integrations like the collaboration with FedEx that highlights the network's potential for massive transaction volume. While the broader market remains volatile, the community is focused on the project's long-term scalability and the potential regulatory tailwinds from the Clarity Act, fueling ongoing debate between those accumulating at these levels and those frustrated by historical price dilution.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently facing intense volatility and downward pressure as investors closely monitor its pre-revenue status and the heavy insider selling that has tempered the enthusiasm from earlier retail rallies. The community remains deeply divided, with bulls pointing to the company's long-term potential as a critical power source for AI data centers and government-backed nuclear initiatives, while skeptics emphasize the significant regulatory hurdles, project timelines, and the lack of current earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CANF Stock Soar 25% Today?

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

<ul class="summary-bullets"><li>Merck said it will reorganize its human health segment into two separate units.</li><li>Merck named Jannie Oosthuizen executive vice president and president of Oncology and MSD International.&nbsp;</li><li>The Specialty, Pharma &amp; Infectious Diseases unit will be led by Brian Foard.</li></ul>Merck &amp; Co. Inc. (MRK) announced on Monday that it is overhauling the leadership structure of its flagship pharmaceutical division as the company prepares for looming revenue headwinds tied to its top-selling cancer therapy.&nbsp;The Rahway, New Jersey-based drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.<h2 class="st-heading-2">Preparing For Keytruda Patent Expiration</h2>One of the units will concentrate on&nbsp;Oncology business, while the other will house the specialty, pharma, and infectious diseases business.&nbsp;According to the Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65">report</a>, the restructuring comes as Merck braces for the loss of U.S. market exclusivity for Keytruda in 2028, a development expected to invite lower-priced competition and dent sales.&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merck stock</a> traded over 1% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory, with message volume shifted to ‘low’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">New Leadership To Drive Growth&nbsp;</h2>To guide the oncology-focused arm, Merck named Jannie Oosthuizen executive vice president and president of Oncology and MSD International. The Specialty, Pharma &amp; Infectious Diseases unit will be led by Brian Foard, who will join Merck effective March 2.&nbsp;<h2 class="st-heading-2">Building Beyond Keytruda&nbsp;</h2>According to the report, Merck has spent heavily on acquisitions in recent years to bolster its pipeline and cushion the anticipated slowdown in Keytruda sales.“As we advance our pipeline and drive commercial success across an increasingly diversified portfolio, including a growing pipeline across Specialty, Pharma &amp; Infectious Diseases, we are sharpening our focus on delivering innovative medicines for patients and creating long‑term value for our stakeholders.”-Robert M. Davis, Chairman and CEO, Merck&nbsp;Merck said it currently has roughly 80 Phase 3 trials underway and anticipates launching more than 20 new growth drivers in the coming years, most of which it believes could achieve blockbuster status.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-tomz-stock-soaring-pre-market-today-a-key-uk-approval-may-be-the-catalyst/cZRt8hkR4y4">Why Is TOMZ Stock Soaring Pre-Market Today? A Key UK Approval May Be The Catalyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Splits Oncology, Specialty Operations To Brace For Keytruda Patent Loss – Overhauls Leadership To Drive Growth 

The drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

<ul class="summary-bullets"><li>Makary urged the Trump administration to partner with the pharmaceutical industry.&nbsp;</li><li>The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind.&nbsp;</li><li>As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.</li></ul>The U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Wednesday reportedly warned that the country is falling behind its Asian rival China in drug development.Makary, in an <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/02/18/fda-chief-warns-us-is-losing-ground-to-china-in-early-drug-trials.html">interview</a> with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.The senior official is of the opinion that there exists multiple bottlenecks that have caused the U.S. to lag behind. Makary recommended that the Trump administration partner with the pharmaceutical industry “to help them deliver more cures and meaningful treatments for the American public.”As per CNBC, China now conducts more clinical trials than the U.S. and accounts for nearly a third of new global drug approvals.<h2 class="st-heading-2">FDA’s Efforts</h2>Last year, the FDA initiated a program called the Commissioner's National Priority Voucher program in a bid to expedite the review of certain drug applications. The program aims to reduce FDA assessment time to one to two months from the standard 10 to 12 months.So far, over 15 drugs from various pharma companies have been awarded the voucher and while one has been approved, another has also been rejected.Earlier this month, FDA refused to approve Disc Medicine’s bitopertin oral tablets for the treatment of Erythropoietic Protoporphyria despite tapping the drug for fast review.However, the agency approved Augmentin XR manufactured by USAntibiotics in December after granting it the voucher. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/IHE"> iShares U.S. Pharmaceuticals ETF</a> (IHE) stayed within the ‘neutral’ territory coupled with ‘normal’ message volume.The ETF closed marginally in the red on Wednesday but has gained about 29% over the past 12 months.Meanwhile, Invesco Pharmaceuticals ETF (PJP) and State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) added 26% and 27%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/carvana-dismisses-short-seller-allegations-as-misleading/cZRK3kWR4wG">Carvana Dismisses Short Seller Allegations As Misleading: Retailer’s Q4 Earnings Disappoint Wall Street</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development

Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

<ul class="summary-bullets"><li>Ocular Therapeutix had reportedly rejected Sanofi’s initial takeover bid in September.</li><li>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology.</li><li>Sanofi recently acquired Dynavax to boost its vaccine portfolio.</li></ul>Ocular Therapeutix (OCUL) was back on retail’s radar, with the stock surging 13% in premarket trading on Thursday, after reports emerged that French pharmaceutical giant Sanofi (SNY) is preparing an offer to acquire the American biopharmaceutical firm.According to French publication La Lettre, the renewed interest comes after Ocular Therapeutix rejected Sanofi’s initial takeover bid in September, when the group offered $16 per share, a substantial premium to Ocular’s then-trading price of about $10.50.<a href="https://stocktwits.com/symbol/OCUL">OCUL shares</a> have been on a downtrend lately, declining in 11 of the last 13 sessions. <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> was down 0.4% in pre-open trade.<h2 class="st-heading-2">Acquisition Rationale</h2>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology, particularly in age-related macular degeneration, which affects the central part of the retina.At the same time, it could support Sanofi’s push into combination therapies, with Ocular’s treatments, such as Dextenza for ocular inflammation, potentially pairing well with existing drugs like Dupixent, given studies suggesting links between chronic skin conditions and eye disorders such as cataracts.<h2 class="st-heading-2">Sanofi’s Acquisition Spree</h2>Sanofi has been ramping up its strategy to add to its portfolio through key acquisitions over the last few months. In late December, Sanofi signed an agreement to acquire vaccine maker Dynavax Technologies Corp (DVAX) in a <a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">$2.2 billion deal</a> aimed at strengthening its adult immunization portfolio. The transaction will strengthen Sanofi’s global vaccines business by bringing in Dynavax’s approved adult hepatitis B vaccine, HEPLISAV-B, along with a differentiated shingles vaccine.In June, Sanofi agreed to <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">acquire Blueprint</a> Medicines for about $9.1 billion to deepen its presence in the cure for rare immunological diseases. The acquisition added Ayvakit/Ayvakyit, the only approved treatment for systemic mastocytosis, along with pipeline assets including Elenestinib and BLU-808 to Sanofi’s portfolio.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for OCUL on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/OCUL_jpg_9ede93e8cf.webp" alt="OCUL.jpg" width="928" height="100"><figcaption>OCUL's Sentiment Meter and Message Volumes at Premarket on Jan. 15, 2026 | Source: Stocktwits</figcaption></figure>One user sees upside in OCUL stock due to the offer.<stembedurl>https://stocktwits.com/scholar9/message/641880419</stembedurl>OCUL shares have gained around 34% over the past year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/nasdaq-sp500-futures-pause-nvda-tsm-msft-cvx-stocks-to-watch/cmU1L2fR47N">Nasdaq, S&amp;P 500 Futures Pause Ahead Of Major Bank Earnings, Jobless Claims: Why NVDA, TSM, CVX, MSFT, AMZN Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did OCUL Stock Jump 13% In Pre-Market Today?

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

<ul class="summary-bullets"><li>The interim data show that ARO-INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat.</li><li>In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.</li><li>ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans.</li></ul>Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 15% in Tuesday’s premarket, after it released early data from its Phase 1/2a clinical trials of its RNA interference (RNAi) therapies, ARO-INHBE and ARO-ALK7, targeting obesity.&nbsp;The preliminary results suggest these investigational treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.<h2 class="st-heading-2">Promising Fat Reduction</h2>The interim data show that ARO-INHBE, especially when combined with tirzepatide, a GLP-1/GIP receptor co-agonist, doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared with tirzepatide alone.The findings mark the first human evidence that targeting the Activin E/ALK7 pathway could enhance weight loss beyond that achieved by existing incretin therapies. In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.On Stocktwits, retail sentiment around Arrowhead stock jumped to ‘bullish’ from ‘bearish’ territory. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_081204_png_73fc92d26b.webp" alt="ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Clinical Highlights</h2>ARO-INHBE monotherapy at week 16 led to a 9.9% reduction in visceral fat, a 38% drop in liver fat, and a 3.6% increase in lean muscle. Two doses at week 24 further improved visceral fat reduction to 15.6% after adjusting for placebo.&nbsp;Combined with tirzepatide, ARO-INHBE achieved roughly double the weight loss and triple the fat reduction compared to tirzepatide alone.ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans, reducing ALK7 mRNA in fat tissue by an average of 88% at the 200 mg dose, with a peak reduction of 94%. Early data also showed a 14.1% reduction in visceral fat after a single dose at week 8, adjusted for placebo.ARWR stock has gained over 227% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-draws-bullish-retail-chatter-ahead-of-key-investor-event-trader-calls-it-potential-multibagger/cmxwMoyR4T0">Ondas Stock Draws Bullish Retail Chatter Ahead Of Key Investor Event – Trader Calls It ‘Potential Multibagger’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

Why Did ARWR Stock Surge Over 15% Pre-Market Today? 

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.

PJP
Invesco Dynamic Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PJP News

PJPInvesco Dynamic Pharmaceuticals ETF